SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a fresh 52-week high amid anticipation of its Q3 earnings report and continued optimism around BRIUMVIs growth. Traders debate whether the rally reflects earnings expectations and business momentum or buyout and short-covering speculation; a potential acquisition remains unconfirmed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure amid approaching midterms, with traders focusing on reports that Trump canceled campaign rallies and on expectations of Democratic gains that could bring greater scrutiny of his administration. Bearish posts dominate, while some bulls argue the selloff could reverse after the election.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

A sharp pullback in ALAB has traders focused on whether it can hold key chart support ahead of earnings, with the report and guidance viewed as a potential catalyst. Bulls call the drop an opportunity amid continued AI data-center demand, while bears point to the stocks rich valuation and concerns about a broader AI-trade slowdown.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines results and weaker outlook have focused attention on soaring jet-fuel costs, which are squeezing margins despite strong revenue and travel demand. Traders are divided between concerns about losses and the airlines heavy debt burden, and hopes that lower fuel prices and premium demand could support a recovery.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Federal cannabis rescheduling is the dominant topic, with traders focused on procedural delays in the DEA process and uncertainty around when a Schedule III decision could arrive. Some see the delays and resulting weakness as an overreaction and a potential buying opportunity, while others are frustrated that the catalyst remains uncertain and has not supported the shares.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

Rising concern about AI-enabled cyberattacks is fueling discussion of SentinelOnes cybersecurity opportunity, while traders also emphasize its lower valuation than peers and speculate about a potential takeover. Those bullish themes are offset by worries about growth, recent financing-related dilution, and weakness across cybersecurity stocks; no acquisition is confirmed.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinears strong quarterly results and higher outlook, driven by accelerating AI data-center optics demand, are the main focus. Traders are divided as the shares sell off despite the upbeat report, with some buying the dip while others point to volatility and weak cash generation as risks.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTXs sharp drop is drawing dip-buying and rebound speculation, while bearish traders warn that further weakness in Bitcoin or Strategy (MSTR) could deepen losses. The debate also centers on the funds 2x daily leverage and volatility decay, which can erode returns when held through choppy markets.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors approaching FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, the revised upper-limb data, and recent commercial job postings. Some see FDA flexibility and INOs approval as encouraging signals, while others caution that hiring is not proof of approval and cite the prior AdCom concerns and efficacy debate.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo shares are under pressure after MaxLinear outlined plans to compete for a share of the 1.6T cable market that Credo currently dominates. Traders debate whether the threat is meaningful given its timeline and expanding demand, while broader AI-sector weakness and insider selling add to bearish sentiment; others view the decline as an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program

(RTTNews) - Addex Therapeutics Ltd. (ADXN, ADXN.SW) on Monday reported a wider net loss for the first half, while operating loss narrowed from last year on lower research and development expenses...

Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

Addex Therapeutics (NASDAQ:ADXN) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.
Benzinga APIs provide real-time access toread more...

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Addex Therapeutics Ltd - ADR

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ADXN Addex Therapeutics announced at 1:00 a.m. Eastern today that its spin-out company, Neurosterix, has completed Phase 1 clinical studies of NTX-253 for schizophrenia and plans to advance the drug into Phase 2 clinical development. This is a genuinely new development since our previous check.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADXN Addex Therapeutics Ltd - ADR

Fundamentals

Latest ADXN News